Price T Rowe Associates Inc. MD Sells 1,572,074 Shares of Hologic, Inc. (NASDAQ:HOLX)

Price T Rowe Associates Inc. MD lowered its position in Hologic, Inc. (NASDAQ:HOLX) by 56.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,229,855 shares of the medical equipment provider’s stock after selling 1,572,074 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Hologic were worth $88,661,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in HOLX. Geode Capital Management LLC lifted its position in Hologic by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider’s stock valued at $412,159,000 after acquiring an additional 144,838 shares during the period. Victory Capital Management Inc. boosted its position in shares of Hologic by 0.5% in the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after purchasing an additional 24,358 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Hologic by 3.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock worth $322,272,000 after buying an additional 129,035 shares during the last quarter. Invesco Ltd. grew its stake in shares of Hologic by 16.4% in the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider’s stock worth $293,434,000 after buying an additional 572,187 shares during the last quarter. Finally, Boston Partners increased its position in Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after buying an additional 1,602,463 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

NASDAQ:HOLX opened at $58.02 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock has a 50-day simple moving average of $61.02 and a two-hundred day simple moving average of $69.93. The firm has a market capitalization of $13.02 billion, a PE ratio of 18.30, a P/E/G ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 52-week low of $55.89 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Upgrades and Downgrades

HOLX has been the subject of several recent analyst reports. Stephens reaffirmed an “overweight” rating and issued a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Morgan Stanley dropped their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Royal Bank of Canada lowered their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Finally, Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.